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Abstract 
 In premenopausal women, the most severe menstrual dysfunction is amenorrhea 
and is associated with chronic hypoestrogenism.  In postmenopausal women, the coincident 
hypoestrogenism observed is associated with a number of clinical sequelae related to 
cardiovascular health.  Due to an observed cardioprotective effect of E2, persistently low E2 
levels in amenorrheic (AM) athletes may confer deleterious effects on cardiovascular health.  
The incidence of amenorrhea among athletes is much greater than that observed among 
sedentary women.   Recent data in AM athletes demonstrate impaired endothelial function, 
elevated low- and high- density lipoprotein levels, reduced circulating nitrates and nitrites, and 
increased susceptibility to lipid peroxidation.  An improvement in endothelial function has also 
been reported during the recovery of menstrual cyclicity in a small sample of previously AM 
athletes.  Although no longitudinal studies exist, these findings are suggestive of increased risk 
of premature cardiovascular disease in AM athletes.  These issues are explored and discussed in 
detail in this comprehensive review paper.  Future research should focus on the presentation and 
progression of these adverse cardiovascular parameters in physically active women and athletes 
with hypoestrogenism to determine their effect on long-term health outcomes.   
 
 
 
Key words: amenorrhea, athlete, endothelium, c-reactive protein, endothelin, E2, homocysteine, 
lipids, nitric oxide, exercise. 
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Introduction 
Unprecedented numbers of women are now participating in physical activity and sport on 
a regular basis [1].  The physiologic benefits of regular exercise are well documented.  However, 
between 2 and 46% of athletic women have reported experiencing amenorrhea (absence of 
menstruation for 3 consecutive months or greater) at any given time, compared to 2-5% of 
eumenorrheic sedentary women [2].  A chronic deficit in energy intake relative to energy 
expenditure is likely the primary cause of exercise-associated amenorrhea [3, 4, 5], although 
insufficient oxidizable metabolic fuel [6], and psychological stress [7] have also been indicated.   
The harmful effects of hypoestrogenism upon bone health in amenorrheic (AM) athletes 
has previously been reported [8, 9].  Specifically, a medical condition termed The Female 
Athlete Triad defines the co-existence of disordered eating, amenorrhea and low bone mass in 
athletes [2, 10].  Since a cardiovascular role for E2 has been identified, impaired cardiovascular 
health has been suggested as an additional clinical sequelae of hypoestrogenism [11]. For 
example, it has been demonstrated that chronically hypoestrogenism exerts unfavorable effects 
upon serum lipids [12, 13], vascular tone [14], hemostatic parameters [15], blood flow [16], 
homocysteine [17, 18], and antioxidant status [19].  However, much of these data derives 
predominantly from studies of postmenopausal women, as well as animal and in vitro models.   
In AM athletes, recent data identifies impaired endothelial function [11], elevated low-
density and high-density lipoprotein levels [20], reduced metabolites of nitric oxide, (nitrates and 
nitrites) [21], and increased susceptibility to lipid peroxidation [22] as potential cardiovascular 
consequences, presumably due to the hypoestrogenism.  Although the clinical significance of 
these consequences remains undetermined, these findings are suggestive of a potentially 
increased risk of premature cardiovascular disease (CVD).   
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This purpose of this paper is to bring together the relevant data surrounding exercise-
associated amenorrhea using both traditional and novel markers of CVD.  Due to the dearth of 
information on AM athletes and cardiovascular health, data derived from postmenopausal 
women, animal models, and in vitro studies are drawn upon to provide an indication of how E2 
status may impact such markers.  While these studies offer insights to the effects of the hypoE2ic 
milieu, there are obvious limitations when extrapolating these findings to AM athletes, i.e., the 
postmenopausal woman is likely to present with multiple risk factors that are inherent with 
aging, whereas the AM athlete will likely have minimal or no risk factors.  Thus, extrapolations 
are intended simply to assist our ability to understand the effects of hypoestrogenism per se on 
key cardiovascular health parameters.  We will also utilize comparisons to anorexic women due 
to similarities in age, menstrual status, and often, exercise behaviors.  Serum lipids, lipid 
peroxidation, nitric oxide, and endothelin are examined in this review.  Due to the predictive 
value of recently identified novel markers to assess risk of future cardiovascular disease or 
events, endothelial function, homocysteine and c-reactive protein are also discussed.    
 
1. Total Cholesterol 
1.1 Introductory Comments: Cholesterol, a waxy, fat like substance, is present in every cell in 
the body.  Functionally, cholesterol is important to cellular membrane structure, as well as to 
synthesize vitamin D, the adrenal gland hormones, and the steroid hormones, namely E2, 
progesterone, and androgens [23].  Cholesterol also plays a key role in the formation of the bile 
secretions that emulsify fat during digestion [23].  Cholesterol is derived from dietary sources 
and is synthesized de novo, predominantly by the liver and intestines, in the cytoplasm and 
microsomes from the two-carbon acetate group of acetyl-CoA [23].  The level of cholesterol 
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synthesis is regulated, in part, by 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) 
synthase, the rate-limiting enzyme in cholesterol biosynthesis [24].  Dietary fat intake, 
specifically saturated fatty acids, also regulates cholesterol levels by increasing the hepatic sterol 
pool and by down regulating LDL receptors, the principle route of clearance of LDL cholesterol 
[25], the primary cholesterol-containing atherogenic lipoprotein (60-70% cholesterol) [26].  The 
other two major classes of lipoprotein particles found in fasted serum are (1) high density 
lipoproteins (HDL), considered the atheroprotective lipoprotein (20-30% cholesterol), and (2) 
very low density lipoproteins (VLDL), primarily a triglyceride-containing lipoprotein (10-15% 
cholesterol) [26].   
The link between blood lipid levels and CVD is well recognized [27,26].  Desirable 
serum total cholesterol (TC) levels are identified as <5.18 mmol/L [26], while elevated TC 
[>5.18 mmol/L] is acknowledged as an independent risk factor for the development of coronary 
heart disease and cerebral vascular diseases [28].  Factors shown to affect TC levels include age, 
gender, heredity, HRT, sedentary lifestyle, cigarette smoking, excessive alcohol intake, 
overweight and obesity, diabetes, diet, and thyroid dysfunction [26,29,30,31,32].  To avoid 
repetition, the impact of hypoestrogenism and exercise on LDL and HDL metabolism are not 
discussed here, but in the relevant sections of this paper. 
1.2  Postmenopausal Women and TC:  Longitudinal data observing the effects of menopause on 
lipid parameters report increased TC, mainly due to increased LDLs and triglycerides, and 
decreased HDLs [39].   Such alterations in TC are predictive of mortality due to CVD [40], and 
are associated with aging (41) and E2 deficiency [32].  Studies have consistently shown that 
postmenopausal women receiving unopposed [33,34, 35] and opposed [33, 36,37,38] HRT 
exhibit reduced TC levels, typically through lowering LDLs, with some data also showing an 
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increase in HDLs, and no consistent effect observed for triglycerides.   The mechanisms of E2 
regulation upon LDL, HDL and triglyceride metabolism are detailed in the respective sections of 
this paper.    
1.3 AM Athletes and TC:  The majority of studies reporting  TC levels in AM and EU athletes 
[22,42, 43,44] show no significant difference between the groups [see Table l].  However, one 
study, which statistically was the only study to have the power to detect differences between the 
groups, reported elevated TC levels in AM compared to EU athletes [20], with borderline high 
levels of TC seen in the AM athletes [5.49 ± 0.16 mmol/L], according to the ATP III [26] 
classification.  Contributing factors to this elevation were not only associated with increased 
LDLs, as seen in postmenopausal women, but also with elevations in HDLs and triglycerides.  
Possible mechanisms for these individual lipoprotein elevations are discussed in the appropriate 
sections of this paper.  The LDL:HDL ratio, identified as a strong predictor of cardiac health in 
men [45] was (1.7) and well below that considered a CVD risk factor [45].  The TC:HDL ratio, 
recently shown to be the best predictor of CVD at any TC level in women [13], was also low 
(2.8) for both AM and EU athletes.   Again, this risk prediction calculation does not place these 
athletes in an “at-risk” category for CVD [13].   
AM athletes consume less dietary fat intake compared to EU athletes [20, 46], although 
identification of types of dietary fat were not specified.  This may be an important consideration 
when undertaking TC assessment since saturated fat has a positive and unsaturated fat a 
negative, correlation with serum TC [25].  Very low fat dietary intake has also been reported in 
anorexia nervosa (AN) patients with some reports of elevated [47] and others of normal [48] TC 
levels.  Where increased TC is observed in AN, it has been attributed primarily to increased LDL 
levels [48].  The paradoxical increase in serum TC despite very low dietary fat intake has related 
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to an abnormality in cholesterol metabolism [49].  More specifically, it has been linked with 
increased synthesis of triglyceride-rich lipoproteins together with an unchanged cholesterol 
synthesis rate [50].  Contrary to this observation, AM athletes do not exhibit increased VLDLs 
(triglyceride-rich lipoproteins) when compared to EU athletes [20], and it is not known if the 
cholesterol synthesis rate is altered in AM athletes.   
Poor overall nutritional status may have contributed to the elevated TC in AM athletes 
reported by Friday and colleagues [20].  This postulate can be directly related to findings in AN 
patients, in that those who present with the worst nutritional status also present with the greatest 
elevations in TC [49].  AM athletes have frequently demonstrated nutritional deficiencies [46,51, 
52] compared to their EU counterparts.  However, on average, the AM athletes participated in 
four extra hours of training per week, thereby creating a potential energy deficit.  It was not 
reported whether the AM athletes with the greatest nutritional deficits also demonstrated the 
greatest alteration to cholesterol metabolism in this study.  Indeed, no data currently exist to 
show whether AM athletes who show the greatest degree of an energy deficit also present with 
the least favorable TC profiles.   
Strikingly similar to AN, although less marked, AM athletes also exhibit hypoglycemia 
and hypoinsulinemia, as well as elevated growth hormone and cortisol concentrations when 
compared to their EU counterpart [53].  The impact of these metabolic aberrations on TC 
metabolism in AM athletes is not known. 
The clinical significance of altered TC levels in AM athletes is not clear.  Elevated LDL 
with concomitantly increased HDL may preserve the cardiovascular risk profile.  Whether TC 
concentrations are impaired due to the hypoE2ic state per se is not known, but it is reasonable to 
postulate that similar cholesterol metabolism alterations may exist between AN patients and AM 
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athletes due to a great number of similar metabolic and to a less extent, dietary aberrations.  
Further studies will help identify the extent of these possible similarities. 
 
2.0 Low Density Lipoproteins 
2.1 Introductory Comments:  The LDL particle is heterogeneous in composition and variable in 
cholesterol content, with small, dense particles having greater atherogenicity than larger, more 
buoyant LDL particles [54].   Functionally, LDL plays a key role in the transport of cholesterol 
to all tissues, but primarily to adipose cells and the liver [23].  Approximately 60-80% of 
circulating LDLs are taken up by the liver via receptor-dependent mechanisms [55,56].  
Apolipoprotein B, the major protein moiety of LDL and other non-HDL atherogenic lipids, acts 
as the ligand to the LDL receptor [54,57].  Hyperlipidemia, diabetes (type I and II), and 
hypothyroidism influence circulating levels of LDL cholesterol [31,58].  In addition, dietary 
cholesterol and fatty acids also influence circulating levels of LDLs, mediated by altering either 
hepatic LDL receptor activity, LDL cholesterol production rate, or both [56].  When cholesterol 
intake is increased, expansion of the pools of sterol, which can be synthesized de novo, occurs 
within liver cells [56].   This results in down-regulation of the LDL receptors, causing a plasma 
increase in the concentration of LDLs [56].  Elevated serum levels of LDLs [>3.37 mmol/L] are 
recognized as an independent risk factor for CVD [26,59,60], and is also associated with 
abnormal vasodilatory function in response to flow-mediated dilatation, facilitating the 
development of atherosclerosis [61].   
2.2  Postmenopausal Women and LDLs:  Premenopausal women have lower LDL levels 
compared to age-matched men [62].  After menopause, LDL levels increase, frequently 
surpassing those of age-matched men, with a trend toward smaller, more dense, and subsequently 
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more atherogenic, particle sizes [63].  The menopausal increase in cardiovascular risk is 
associated with unfavorable elevations in TC, triglycerides and lipoprotein (a), an LDL-like 
lipoprotein [12,13,54].   In an extensive review, Schwertz & Penckofer [64] identify that 25 – 
50% of the potential cardioprotective effect of E2 are associated with its effect on blood lipids 
and lipoproteins.  The impact of E2 on serum lipids derives primarily from E2-receptor-mediated 
effects on the hepatic expression of apolipoprotein genes [65,66,67].   Endogenous E2 [68] and 
E2 therapy, both transdermal and oral [69,70], reduce circulating LDL levels. This E2-associated 
lowering effect has been attributed to an increased catabolic rate of hepatic cholesterol into bile 
acids [71] and increased expression of LDL receptors on cell surfaces [72,73].  In contrast to 
this, the post-menopausal, hypoE2ic milieu causes reduced LDL receptor activity [54], 
contributing to the well documented elevation in plasma LDL concentrations in this population.   
2.3 AM Athletes and LDLs:  Studies observing LDL levels in AM athletes [20,42,44] are 
equivocal, due, in part, to variable methodologies and small sample sizes.  These data are shown 
in Table ll.   Investigators have reported significantly elevated LDL levels [20,46], as well as 
non-significantly different LDL levels [42,43] in association with comparable apolipoprotein B 
levels [43,44], in AM compared to EU athletes. It is not clear whether these alterations are of 
clinical significance.  Interestingly, elevated LDL levels have been observed in those studies of 
AM athletes that show statistical significance [46] or a strong trend [20] for both reduced caloric 
intake and dietary fat intake.   
 The paradoxical increase in circulating LDL despite reduced dietary fat intake is 
consistent with findings in chronically hypoE2ic AN patients [49].  Normal or elevated levels of 
TC in AN has predominantly consisted of increased LDL levels, despite typically very low 
dietary cholesterol intake and a normal cholesterol synthesis rate [49].  Mechanisms for this 
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phenomenon in this patient group are associated with the known down regulatory effect of 
altered thyroid hormones; i.e. reduced total triiodothyronine (T3), and lowered E2 levels [49] on 
the cellular number of hepatic LDL receptors [72,74], thereby contributing to increased plasma 
LDL levels [74].   Similarly, but less marked, hypoE2ic AM athletes have also displayed low 
total T3 status [75,76], as well as lower caloric intake [46], and perhaps most notably, 
significantly less calories derived from dietary fat [20,46,77] when compared to their EU 
counterparts.  These findings lend credence to the possibility that, although less severe than 
observed in AN patients, the metabolic aberrations observed in AM athletes may, in part, explain 
the reported elevations in LDL levels in AM athletes.  This avenue of potential application merits 
further exploration. 
It is possible that along a continuum of dietary restriction, the AM athletes that 
demonstrate the greatest nutritional aberrations will also demonstrate the least favorable LDL 
profiles.  Further, down regulation of LDL receptors due to hypoestrogenism and altered thyroid 
status may likely play an important role in cholesterol metabolism in AM athletes, although this 
issue has not yet been closely examined.  In addition, hypoestrogenism may prove to have a 
more deleterious effect upon LDL metabolism in AM athletes as a function of time i.e., the 
longer the episode of amenorrhea the greater the risk of elevated LDL.  This possible long-term 
effect of hypoestrogenism has yet to be confirmed.   
 
3.0 High-Density Lipoproteins 
3.1 Introductory Comments:   HDL particles correlate inversely with the risk of CVD [54], and is 
acknowledged as being anti-atherogenic [78]. The cardioprotection afforded by HDL in the 
prevention of CVD originates from the role of reverse cholesterol transport whereby HDL is 
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postulated to scavenge surplus cholesterol from peripheral tissues for delivery to and disposal by 
the liver for excretion via the bile [63,79].  Important to cellular cholesterol homeostasis, reverse 
cholesterol transport is proposed to be a result of apolipoprotein A-I promotion of cholesterol 
efflux from the cells via receptor (scavenger receptor B type I), and non-receptor (passive 
diffusion) mediated mechanisms [80].  Apolipoproteins A-I  and A-II are the two major proteins 
associated with HDLs [79].  
In addition to the above recognized properties, HDLs have also demonstrated anti-
thrombotic [81], and favorable vascular tone [82] effects, including enhanced endothelial 
function [61].  The antioxidant properties of HDL can be directly related to studies that show 
HDL attenuates LDL oxidation [83], inhibits the atherogenic effect of oxidized LDLs [84], as 
well as increasing the half-life of endothelial nitric oxide [82], all of which are recognized 
processes that contribute to healthy endothelial function.   
Taken together, these data endorse the postulation that HDLs may in some way protect 
against the development of atherosclerosis and heart disease via both cholesterol-dependent and 
–independent mechanisms. 
3.2 Postmenopausal Women and HDLs: Although consistently higher in women than men during 
all life stages after puberty [85], HDL levels tend to decrease in postmenopausal compared to 
premenopausal women [86], with significant reductions effected as a consequence of menopause 
[39].  Bilateral oophorectomy also results in decreased circulating levels of HDLs [87].  
Diminished levels of circulating E2 plays a key role in these observations, in part, due to the 
known E2ic stimulatory effect on apolipoprotein-A1 [88].   Evidence supporting a beneficial role 
of E2 upon HDL metabolism can be also be supported from examination of the exogeneous 
administration of E2  [89, 90].  Following E2 replacement therapy, Pickar and colleagues [89] 
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observed that HDL-2, the main subfraction of HDL found to increase in response to E2 therapy, 
resulted in enriched HDL phospholipids, thereby promoting an elevation in apolipoprotein AI 
production while maintaining similar metabolic clearance of HDLs.  Thus, E2s not only modify 
HDL levels, but also its lipid composition and distribution, thereby augmenting the plasma 
capacity to execute cholesterol efflux [91].   
3.3 AM Athletes and HDLs:   Several investigators have evaluated serum HDL levels in 
AM athletes (Table lll).  Finding have been variable, including significantly elevated [20], 
similar [22,42,43,46] and non-significant trends toward lower [22,42] HDL concentrations in 
AM athletes when compared to EU athletes.  However, consistent with the observation that 
endurance trained athletes possess much higher HDL levels compared to sedentary populations 
[96], EU and AM athletes demonstrate significantly increased HDL levels compared to EU 
sedentary controls [46,43].  In addition, AM athletes, despite a hypoE2ic milieu, exhibit elevated 
HDL levels [20] such that,  it can be considered a negative risk factor, thereby negating the 
presence of another single risk factor [26].  Friday and coworkers [20] postulate that the extra 4 
hours of weekly exercise participation in the AM compared to EU athletes in their study likely 
contributed to these greatly elevated levels of HDLs.   
Elevations of HDL levels in AM runners have also been associated with volume of 
exercise training, with the highest levels observed in those running the greatest distances 
(>64km/week). The observed improvements in HDL concentrations with increased running 
distance demonstrates the favorable effect of endurance exercise on cardiovascular risk, 
irrespective of menstrual status, and are suggestive of E2-independent mechanisms effecting the 
HDL increase.  Indeed, the primary mechanism for the exercise-induced elevation has been 
postulated to be due to increased skeletal muscle and/or adipose lipoprotein lipase activity, 
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resulting in accelerated breakdown of triglyceride rich lipoproteins, facilitating plasma clearance 
and provision of free fatty acids as a fuel source for muscle metabolism or adipocyte storage 
[98].  However, the activity of lipoprotein lipase was not assessed by Friday and coworkers [20] 
and can only be speculated as a consequence of a greater volume of endurance activity in the 
AM versus EU athletes.   Despite this, the aforementioned observations demonstrate a robust 
relationship between endurance exercise and HDL cholesterol concentrations, independent of 
menstrual status. 
 Women with AN have also been reported to have reduced circulating HDL levels, a 
consequence hypothesized to be a product of their previously discussed hypometabolic profile 
[93].  This observation can be explained in part by the finding that total T3 is a potent mediator of 
apolipoprotein-I gene expression [94].  Consequently, when T3 is reduced, apolipoprotein-I gene 
expression is also reduced, causing diminished HDL levels.  Although not evaluated 
simultaneously in any of the studies measuring HDL levels in AM athletes, Loucks et al. [76] 
and others [75,95] have documented significant reductions in T3 levels in AM compared to EU 
athletes.  It is reasonable to suggest that the presence of reduced T3 in AM athletes may serve as 
one pathway by which circulating apolipoprotein-I levels can be negatively impacted.  However, 
apolipoprotein A-I levels have been shown to be comparable in AM compared to EU athletes 
[20,44], and when comparing AM athletes to EU sedentary controls [44].  It would be interesting 
to evaluate all of these parameters in a single study.  
4.0 Triglycerides 
4.1 Introductory Comments:  Triglycerides (TG) are esterified fatty oils that form the core of 
chylomicrons and VLDL cholesterol and are comprised of a glycerol and three free fatty acid 
molecules [23]. TG metabolism is met by two pathways, the exogenous and endogenous cycle. 
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The exogenous cycle is responsible for processing dietary fat, while the endogenous cycle 
involves internal production of triglyceride-rich lipoprotein particles that are manufactured in the 
liver [99]. Recent recommendations for TC from the National Cholesterol Education Program 
[26] propose that TG are an independent risk factor for CVD, with desirable levels being <1.7 
mmol/L.  The association between elevated TG levels and CVD is not well defined and remains 
somewhat controversial.  This is, in part, due to the close inverse metabolic association between 
TG and HDL [100], and the documented co-existence of elevated TG with other CVD risk 
factors, such as hypertension and abdominal obesity [100]. These associations have made 
isolated assessment of elevated TG as a predictor of CVD problematic.  Further, TG 
measurement may not accurately reflect CVD risk status due to the lack of informative regard to 
the specificity of the TG-rich lipoproteins that are present in plasma [99,101].  For example, 
some TG-rich lipoproteins are highly heterogeneous in terms of size and lipid composition, such 
as, chylomicrons and large VLDL, which are thought to be unable to enter the arterial wall, and 
therefore considered non-atherogenic[101].  Conversely, small very low- and intermediate-LDLs 
can enter into the arterial intima, and as such, are considered highly atherogenic [99,101].  As 
such, VLDL is the most readily obtainable measure of atherogenic remnant lipoproteins [26].   
A number of factors contribute to higher than normal TG levels [>1.7 mmol/L] in the 
general population, including obesity, being overweight, physical inactivity, cigarette smoking, 
excess alcohol intake, high-carbohydrate diets [>60% of energy intake], several diseases, such as 
type II diabetes, chronic renal failure, and nephrotic syndrome, and certain drugs including 
corticosteroids, E2s, retinoids, higher doses of beta-adrenergic blocking agents, as well as 
heredity factors [26]. 
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4.2  Triglycerides and Postmenopausal Women:  TG profiles undergo unfavorable changes in 
menopause and are reported to be elevated in postmenopausal women [12]. This increase can be 
linked to a strong relationship between excess visceral fat accumulation (android adiposity) and 
TG levels in postmenopausal women [102]. This type of fat distribution among women, 
postulated to be due to hypoestrogenism [103], is associated with unfavorable alterations in the 
lipid profile, such as increased LDL and TC and decreased HDL concentrations [102].  Such 
findings support the postulate that the co-existence of other CVD risk factors is associated with 
elevated TG.   
At the level of the liver, orally administered HRT increases TG levels [104,105].  This is 
augmented by the hepatic synthesis of VLDL, particularly of the large TG-rich particles, as well 
as the inhibition of hepatic triglyceride lipase [15,106].  Despite this HRT-associated elevation in 
TG levels, concomitant favorable effects of HRT administration include decreased LDL and TC, 
as well as elevated HDL levels [106].  It is generally accepted that the anti-atherogenic effect of 
HRT upon LDL, HDL and TC outweigh the deleterious effect of elevated TG levels.   
4.3  Triglycerides and AM Athletes:  Studies measuring TG levels in AM athletes  report non-
significant [22,42,44] and significant [20] elevations, compared to the EA.  Table IV illustrates 
these studies.  Despite the majority of these findings being equivocal, observation of consistently 
greater TG concentrations in the AM compared to EU athletes represents what seems to be part 
of a ‘trend’ in the lipid profiles of these athletes. To date, no studies have reported assessments 
of TG-rich lipoproteins, such as VLDL, for the determination of atherogenic versus non-
atherogenic TG particles.   
Since TG are frequently associated with other CVD risk factors rather, such as low HDL, 
elevated LDL and TC, it is interesting to note that the one study to report significantly elevated 
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TG in AM athletes [20] also reported significantly elevated LDL and TC.  However, the reported 
level of TG for AM athletes by Friday and colleagues [20] does not represent a value outside of 
the normal range [>1.7 mmol/L] as stipulated by the NCEP [26].   
That TG was elevated in AM athletes compared to their sedentary counterparts [43,44] is 
consistent with data from AN patients [111] but not consistent with studies that show TG 
concentrations that are frequently lower in endurance athletes when compared to sedentary 
controls [107].  Cross-sectional data also identify similar TG concentrations in female athletes, 
irrespective of menstrual status and reported distance (0-139 km) run each week, [97].  These 
findings are suggestive of E2- and exercise-independent mechanisms in TG metabolism, 
although it is likely that an interaction exists between these two variables since research shows 
that menopause-associated hypoestrogenism increases [12] while endurance exercise decreases 
[107] TG concentrations.  These data further highlight the potentially impaired utility of 
assessing TG in populations that are less likely to present with elevated TG in as much that other 
TG-associated CVD risk factors are absent.   However, more subtle alterations to TG 
metabolism, such as a shift from non-atherogenic to atherogenic TG lipoprotein metabolism may 
be occurring, potentially necessitating closer examination of the TG composition rather than the 
absolute presence of TG presence per se.    
As previously mentioned, low T3 is associated with a pro-atherogenic lipid profile [31], 
suggesting that nutritional status may be an important consideration when assessing TG levels in 
AM athletes. A high-carbohydrate diet has been shown to increase fasting TG levels [108], while 
very low-carbohydrate intake has recently been demonstrated to significantly reduce fasting TG 
levels as well as favorably impact HDL and the TC/HDL ratios in normal weight 
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normolipidemic women [109]. Future research efforts should pursue the interactions among 
these variables. 
The physiological significance of the reported elevated concentrations of TG in AM 
athletes is not clear.  The possible mechanism behind this observation is not known.  The 
inclusion of specific assessment of TG-rich lipoproteins may yield more pertinent information 
with regard to atherogenic compared to non-atherogenic TG particles. 
 
5.0.  Lipid Peroxidation  
5.1  Introductory Comments:  Elevated free radical production can negatively influence the 
oxidative status of circulating LDL particles [112]. Oxidative modification of LDL vastly 
elevates its atherogenicity [113] and has been implicated in the initiation and progression of 
atherosclerosis [114].  Increasing evidence supports that oxygen-derived free radicals, namely 
reactive oxygen species, are associated with destructive biological processes, including DNA and 
cellular membrane damage [115].  Chronic age-related disease states such as diabetes and 
carcinogenesis, as well as strenuous physical exercise have been implicated [116,117,118].  
Reactive oxygen species incorporates hydrogen peroxide, and the less stable, superoxide- and 
hydroxyl- free radicals [22,119].  The magnitude of the oxidative stress is determined by the 
capacity of the antioxidant defenses to detoxify reactive oxygen species [120A].  Intracellular 
enzymatic antioxidant defenses include glutathione peroxidase, glutathione reductase, superoxide 
dismutase, and catalase [115,121], all of which reduce the susceptibility of the cell to potentially 
harmful free radicals [121].  In addition, non-enzymatic extracellular antioxidant defenses also 
exist, including vitamin E (alpha-tocopherol), vitamin A (beta carotene), and vitamin C (ascorbic 
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acid) [122].   It is the balance between reactive oxygen species production and antioxidant 
defenses that determines the degree of oxidative stress [119].   
5.2 Lipid Peroxidation in Postmenopausal Women and Other Low E2 Models:  Research 
surrounding lipid peroxidation and the effect of exogenous and endogenous E2 demonstrate 
inconsistencies.  Antioxidant effects of E2 on LDL in vivo [123,124] and in vitro 
[114,125,126,127] have been confirmed.  Conversely, no effect [128] for E2 on antioxidants in 
vivo has been documented.  Differences in model utilization, subject demographics, and E2 
administration, dosage, time frame, and type, have, in part, contributed to the discrepancies 
found in the research.   
 E2s may protect from atherosclerosis by inhibiting LDL oxidation [129]. Endogenous 
E2s have free radical-scavenging abilities, with up to 2.5 times the activity of vitamin C and E 
[130].  E2s ability to form moderately stable radicals from less stable radicals by donating a 
hydrogen atom is consistent with antioxidant function [130]. This antioxidant capability has been 
evidenced in premenopausal women who have significantly higher estradiol levels and lower 
lipid peroxide concentrations, as well as significantly higher glutathione peroxidase activity 
when compared to postmenopausal women [131].  In addition, significant increases in 
endometrial glutathione peroxidase have been observed during the high E2 phase of the cycle 
[132].  Such data support a beneficial effect for endogenous E2 on both intracellular antioxidant 
enzyme activity and free-radical scavenging abilities against lipid peroxidation.  
5.3  Lipid Peroxidation in AM Athletes:  There is no single biomarker that is considered the "gold 
standard" of lipid or protein oxidation [133].  However, evidence for oxidative stress during, and 
post, exercise can be obtained from measurement of free radicals, the assessment of damage to 
lipids, and from measurement of antioxidant redox status, particularly glutathione [134].  
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Considering the reported antioxidant effect of endogenous E2 [123], and exercise training [135] 
surprisingly few studies [22,42,136] have investigated the effects of amenorrhea on lipid 
peroxidation and oxidative status in AM athletes.  These studies report significantly decreased 
LDL diene conjugation, i.e, a decreased ability of LDL to resist peroxidation [22], and a greater 
[42] as well as similar [136] magnitude of change for lipid peroxidation potential post-exercise in 
AM compared to EU athletes.  Kanaley and Ji [136] also report that at rest and post-exercise, 
AM athletes demonstrate significantly elevated glutathine peroxidase compared to EU athletes, 
and that malondialdehyde, an indirect indicator of lipid peroxidation, is similar in both groups.  
In addition, oxysterol formation, derived from the enzymatic and non-enzymatic oxidation of 
cholesterol [137], is increased post-exercise in AM athletes only [22].  Collectively, these 
findings are conflicting and do not provide answers as to whether exercise in the face of 
hypoestrogenism affects antioxidant status. This can be attributed, in part, to the fact that each 
study utilized a different exercise protocol, including a maximal oxygen uptake test [42], as well 
as a 30 minute [22] and a 90 minute submaximal running bout [136]. It is also possible that the 
exercise intensity and/or duration of exercise may have been insufficient to stimulate an oxidant 
response due to the high level of aerobic fitness of the athletes.  Training status of the athletes 
was also not consistently reported.   
An important factor to consider when assessing antioxidant defense mechanisms are the 
training, as well as the adaptive, status of the athlete [138].  In the studies reporting the 
antioxidant status of AM athletes, training status was reported as mileage per week [22,136], 
duration of training [22], or not reported [42]. None of these studies reported the adaptive status 
of the athletes, thereby further compounding the lack of clarity regarding interpretation of E2 
status on antioxidant status.  However, despite conflicting findings, the elevated glutathione 
Cardiovascular status in amenorrheic athletes                                                   Page 21 
peroxidase levels in AM compared to EU athletes [136] is indicative of an enhanced 
antioxidative status in the AM athlete, despite a hypoE2ic environment, suggesting alternative 
antioxidant mechanisms [136], such as training status.  Indeed, research has shown that well 
trained and well adapted athletes demonstrate an augmented antioxidant system and a reduction 
in lipid peroxidation [135], as well as greater resistance to exercise-induced or -imposed 
oxidative stress [139,140,141]. Consistent with this finding is the observation that total 
antioxidant status is positively correlated with VO2 peak in runners [142], supporting the theory 
of a stress-tolerance mechanism, whereby enzymatic antioxidant defenses are enhanced due to 
exercise training per se.   
In contrast to the adaptive oxidative status of the well trained athletes, higher 
performance and training levels are associated with greater elevations in exercise-induced lipid 
peroxidation [143], resulting in an antioxidant system that can become overwhelmed and unable 
to cope with the increased free-radical production [138].  This occurrence can be linked with 
overtraining [144], exercise training intensity [145], and/or the nutritional status of the athlete 
[146], whereby susceptibility to antioxidant deficiency may occur [146].  However, since no 
studies to date have confirmed an effect of E2 upon anti-oxidant status in humans in response to 
exercise [133], it is likely that the anti-oxidant status in AM athletes is reflective of the training 
and/or adaptive status, the nutritional status, and or the hypoE2ic milieu. 
Consistent with previous research reporting the effect of an acute bout of strenuous 
exercise on anti-oxidant defenses [147], a decreased capacity to detoxify ROS after a maximal 
bout of exercise, as demonstrated by unfavorably altered oxysterol formation and increased lipid 
peroxidation levels in AM athletes [22] has been observed.  These findings do imply a 
compromised antioxidant status in AM athletes, and that an increased potential risk for 
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premature atherosclerosis may be present.  However, (1)  a single maximal bout of exercise is 
not necessarily reflective of a regular training session for the athletes, and thereby not 
representative of the characteristic oxidative stress these athletes might otherwise incur; and (2) 
it is normal for oxidative stress to be elevated after strenuous exercise [147], and as such, 
recovery data rather than immediate post exercise data might provide more relevant information 
about antioxidant status.  In addition, since non-enzymatic antioxidants are negatively correlated 
with lag time of diene conjugates [22], assessment of dietary supplementation may also be an 
important aspect of oxidative stress determination, particularly in the AM athlete [22].   
The impact of sustained hypoestrogenism in the AM athlete upon the oxidative system is 
not clear, but data indicate that the antioxidant defenses of the AM athlete may be compromised 
after strenuous aerobic exercise.  Inclusion of training, adaptive, and dietary status will help 
minimize confounding factors.  Data suggest that in well trained individuals exercise training 
elicits favorable effects upon the oxidative milieu [140].  Since higher exercise intensity appears 
to effect a greater oxidative response in AM compared to EU athletes after maximal exercise 
[22], studies to determine the oxidative stress response to high exercise intensity training in AM 
athletes are worthy of further investigation.  Mechanism(s) underlying the combined E2- and 
exercise-mediated protection of lipid peroxidation need to be determined.  In addition, 
methodological consistency in measurement of antioxidant enzymes needs to be established. 
 
6.0 Nitric Oxide 
6.1 Introductory Comments:  The endothelium is a multifunctional interface between the 
circulating blood and various tissues and organs of the body [148], and is recognized as a 
metabolically active organ that is vital to vascular homeostasis [149,150].  Through the 
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combined release of vasoactive substances, such as nitric oxide and endothelin, endothelial 
hemostatic function is realized. Nitric oxide is a potent vasodilator [151] that also maintains a 
low resting arterial tone in the peripheral [152] and pulmonary [153] circulations.  Nitric oxide 
also inhibits platelet aggregation, suppresses smooth muscle cell proliferation and acts as an 
antiatherogenic factor [154,155].  Endothelial-derived nitric oxide is produced by the endothelial 
isoform of nitric oxide synthase upon the conversion of the substrate L-arganine to L-citrulline 
[155].  The production of this free radical messenger has been identified as effecting a protective 
role on the endothelium [150].  Impaired release and/or bioavailability of nitric oxide has been 
linked with hypertension [156], hypercholesterolemia [157], diabetes [158], tobacco use [159], 
established coronary artery disease [160], and E2 deficiency [161].  Consequently, factors that 
decrease nitric oxide production and/or bioavailability may promote atheroslcerosis [162]. 
In endothelial cells, gene expression of nitric oxide synthase (NOS), despite being 
constitutively activated, can also be up-regulated by both receptor-mediated (ie acetylcholine, 
serotonin, thrombin, bradykinin) and receptor-independent (ie shear stress) mechanisms [161].  
A number of pathways leading to the release of vascular nitric oxide have been identified, 
including: (1) basal endothelial release that maintains low vascular tone; (2) mechanical stimuli, 
that is, increased shear stress; (3) dilating factors, (i.e. prostaglandins) and metabolites (i.e. 
adenosine) released from contracting skeletal muscle; (4) nitroxidergic and (5) cholinergic nerve 
stimulation, and (6) nitric oxide release from skeletal muscle [163].  The multiplicity of 
pathways to attain vascular nitric oxide release identifies this free radical messenger as a key 
modulator of vessel function.    
6.2 Nitric Oxide in Postmenopausal Women 
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A plethora of data regarding the effect of E2 and HRT upon endothelial function in 
women have been published [for review, see 164].  Most [14,165,166] but not all [167] reports 
support a role for  E2 increasing endothelium-dependent flow-mediated vasodilation.  In vitro 
data also show an endothelium-independent, that is, a direct smooth muscle-relaxing effect, of 
17-beta estradiol upon the coronary arteries in human females [168]. Blunted circulating levels of 
nitrite/nitrate [169], in addition to increased plasma levels of endothelin-1 [170], and impaired 
endothelium-dependent [171] and –independent [172] function occurs in postmenopausal women 
not receiving E2- or HRT.  Further, recent data demonstrate that acute (7 days) E2 deficiency 
due to ovariectomy is associated with unaffected endothelial function [173], as well as impaired 
endothelium-dependent, but not –independent vasodilation [162] in response to flow-mediated 
dilation.  The reason for differing findings between these studies [162,173] is not clear.    Taken 
together these data suggest that reduced circulating levels of E2 may effect impaired endothelial-
dependent and -independent function, and is associated, in part, with reduced nitric oxide 
production and/or bioavailability [169].   Further, 17-beta estradiol may have an important 
regulatory role in coronary arterial tone [168] due to possible direct effects upon endothelium 
and smooth muscle cells. 
6.3 Nitric Oxide and AM Athletes:  Despite the well documented E2-nitric oxide association, 
only one study documenting nitric oxide levels in AM athletes has been reported.  Stacey et al., 
[21] observed significantly decreased levels of plasma nitrate/nitrite production despite 
significantly elevated dietary ingestion of nitrates in AM athletes compared to sedentary EU 
women.  Since chronic aerobic exercise enhances blood flow and shear stress [174], and 
strenuous exercise can incur striking increases in plasma [175] and urinary [176] nitric oxide 
metabolite concentrations, it is interesting that despite participating in chronic endurance 
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activities, the AM athletes did not demonstrate increased nitric oxide concentrations.  
Consequently, the reduced plasma nitrite/nitrate levels are hypothesized to be related to the 
chronically low E2 status of the AM athletes [21].  The clinical consequence or physiologic 
relevance of this observation is not known.   
Although no other studies report nitric oxide levels in AM athletes, some data alluding to 
the E2-nitric oxide association through observation of vascular response to flow-mediation 
dilation, an endothelium-dependent, and therefore a predominantly nitric oxide mediated event, 
does exist.  Zeni-Hoch and co-workers [11] were the first to demonstrate that, similar to 
postmenopausal women, young AM athletes (21.9 ± 1.2 yrs) also present with endothelium-
dependent, but not –independent, dysfunction compared to their oligomenorrheic and EU 
counterparts. Resting heart rate, mean arterial blood pressure and baseline brachial arterial 
diameter, were similar between the groups, yet mean percent change from baseline brachial 
artery diameter in response to flow mediated dilation in AM and EU athletes was 1.08 ± 0.91% 
and 6.38 ± 1.38 %, respectively [11].  Alarmingly, the magnitude of impaired brachial 
endothelium-dependent vasodilation in AM athletes is comparable to data previously reported in 
otherwise healthy postmenopausal women [177] and older [60 ± 2yr] coronary artery diseased 
patients [178] after a similar flow-mediated stimulus.  Since endothelial dysfunction is a 
predictor of future coronary events [179], the finding from Zeni-Hoch and colleagues [11], is 
suggestive of increased risk for accelerated cardiovascular disease development in AM compared 
to EU athletes [11].   
Secondary to chronically diminished circulatory E2 levels, reduced circulatory nitric 
oxide [ref] is a likely contributing factor responsible for the observed endothelial dysfunction in 
AM athletes.  However, Zeni and colleagues [11] did not specifically attribute the impaired 
Cardiovascular status in amenorrheic athletes                                                   Page 26 
endothelial dilatory response in AM athletes to E2 deficiency, perhaps because each group 
presented with similar E2 levels at the time of testing.  However, chronically suppressed versus 
cyclical fluctuations of E2 levels would likely be better identified with daily urinary analysis of 
metabolites of E2 rather than a single blood draw.  In addition, a single blood draw assessment 
cannot identify the possibility of an effect of E2 exposure across time upon endothelium-
dependent function in active women with less severe menstrual disturbances, such as, 
anovulation, or oligomenorrhea.  That oligomenorrheic and EU athletes showed similar 
responses for flow-mediated dilation [11] is suggestive of a “critical threshold of E2 exposure”, 
and that some E2, as oligomenorrheic athletes are likely exposed to, is better than none, i.e., the 
chronically low levels AM athletes are exposed to.   
An additional demonstration of the importance of E2 to vascular function can be realized 
from data on resumption of menses in these same AM athletes, as reported by Hoch [180]. 
Resumption of menses restored endothelial-dependent function in the AM athletes to levels 
observed for EU athletes [180].  This reversibility in endothelial-dependent function with return 
of ovarian function is consistent with data that show improved endothelial function in post-
menopausal women after HRT [14]. Mechanisms of non-genomic vasodilatory effects of E2 
includes stimulation of the opening of calcium-activated potassium channels [181], and 
activation of endothelial nitric oxide synthase, the precursory enzyme of endothelium-derived 
nitric oxide [161], via E2 receptor-alpha mediated activation [182], with heat shock protein 90 
acknowledged as a key requirement to this activation [183].  Dependent pathways include E2-
receptor mediated mitogen-activated protein kinase [182] and phosphatidylinositol 3 (-Akt [183].  
The impact of hypoestrogenism on these pathways, however, is not well understood, but it is 
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reasonable to expect that AM athletes may demonstrate impairment in one or both of these 
pathways.  
There is a positive correlation between cardiovascular fitness and endothelial function 
[184].  Accordingly, evidence suggests that endothelial dysfunction limits exercise capacity, 
either via central or peripheral mechanisms [185].  Conversely, exercise is efficacious in 
restoring dysfunction of the vascular endothelial nitric oxide system [186].  The exact 
mechanisms for this effect are not yet understood.  Decreased endothelial nitric oxide may also 
be rate-limiting to oxygen delivery and exercise performance [187].  Data show, however, a lack 
of correlation between cardiovascular fitness, exercise capacity and endothelial function in AM 
athletes, despite being demographically similar to EU counterparts, including weekly mileage, 
duration of training, and 5km race time [11].  These findings imply that exercise-associated 
amenorrhea does not impact athletic performance, but may be implicated as a potential negator 
of the known cardioprotective benefits of aerobic exercise [11].  Impaired endothelial function 
despite chronic endurance training in AM athletes suggests that hypoestrogenism may exert a 
greater negative effect than the positive effect of aerobic exercise per se.   
Mechanisms explaining the difference in endothelial function of EU and AM are not yet 
known, but are likely related to hormonal regulation of endothelial function which may be the 
result of receptor-dependent or -independent mechanisms [188].  Progesterone-, androgen-, and 
E2-receptors have been identified in human vascular endothelium [188].  Two functionally 
different receptor sub-types for E2ic actions exist, E2 receptor-alpha and -beta, although the 
importance of these sub-types in the vasculature remains unclear [189].  Expression of E2 
receptor-alpha has been observed in human endothelium [190] and vascular smooth muscle cells 
[191].  E2 receptor-beta expression in vascular tissue is less well distinguished, but has been 
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detected predominantly in vascular smooth muscle cells [189], identifying a potential 
endothelium-independent role for E2.  Several target genes for E2s have also been identified, 
including those encoding proteins that modulate lipid clearance, cardiac contractility, cell 
proliferation, and specifically, vascular tone [192]. Consequently, the presence of vascular E2 
receptors is associated with protection against coronary atherosclerosis [193], and their 
expression is directly impacted by the level of circulating E2s [193].   
The effect of sustained impaired endothelial function upon atherosclerotic development 
or vessel integrity in AM athletes awaits investigation.  To date, the clinical and health 
implications of prolonged E2 deficiency upon the vasculature in AM athletes is not clear.  
Further, the time-course of decline in endothelial function, a potential “critical threshold of E2 
exposure”, and changes in endothelial function with resumption of menses, or perhaps 
exogeneous hormones, should be explored in future research. 
 
7.0 Endothelin 
7.1 Introductory Comments:  Endothelial integrity, essential for normal functioning of blood 
vessels, is preserved not only by endogenous vasodilative, but also by vasoconstrictive 
substances, such as endothelins (for review, see [194]).  Alteration of the nitric oxide and 
endothelin-1 (ET-1) systems is augmented by, and is associated with, many cardiovascular 
diseases [195].  The vasoconstrictive production of endothelin however, can be inhibited by 
nitric oxide [195].  Endothelins (ET-1, ET-2, ET-3) are biologically active peptides that oppose 
the effects of nitric oxide through vasconstrictive and mitogenic action [196,197].  Of the three 
endothelin isoforms, however, only ET-1 is constitutively produced by the endothelial cells, 
making ET-1 a key vascular regulator [194]. Via endothelin smooth muscle receptors, 
Cardiovascular status in amenorrheic athletes                                                   Page 29 
endothelin-A (ET-A) and -B (ET-B), and  endothelial cell receptor, ET-B, endothelium-derived 
ET-1 predominantly facilitates vasoconstriction [195], although stimulation of endothelial cell 
ET-B receptors can also oppose ET-A and ET-B mediated vasoconstriction by stimulating nitric 
oxide formation [195].  This vasodilatory response is due to increased intracellular calcium, 
resulting in upregulation of endothelial nitric oxide synthase [194].  In addition to 
vasoconstrictive and vasodilatory properties, endothelins also increase monocyte adhesion, 
macrophage activation, and vascular smooth muscle cell proliferation and migration through ET-
A and ET-B [198].  Due to the observation that altered expression and/or activity of ET-1 can 
lead to the development of vascular diseases [194], ET-1 has been implicated in the progression 
of atherosclerosis [154].  
7.2 Endothelin and Postmenopausal Women:  Research surrounding ET-1 and postmenopausal 
women is less plentiful than that found for nitric oxide.  Typically ET-1 levels have been shown 
to be elevated in postmenopausal women [199,200], and are significantly reduced with 
administration of HRT [199,200].  Chronic (6 months) E2 therapy results in decreased levels of 
endothelin, as well as an increased ratio of nitric oxide to ET-1 [196].  In addition, ET-1 
mediated arterial constriction has been shown to be reduced after one month of treatment with 
estradiol [2mg/day] in older postmenopausal patients when compared to placebo [201].  This 
reduction is suggestive of an estradiol effect on endothelium-dependent vasoconstrictive 
responses, which may incorporate nitric oxide and/or prostaglandins [201].  Interestingly, long 
term [3 months] oral estradiol administration [2mg/day] resulted in a loss of the E2-inhibitory 
effect upon ET-1 mediated arterial constriction, implying possible tachyphylaxis, that is, an acute 
loss of response, due to sustained high doses of estradiol [201].   
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One potential explanation by which E2 may impart favorable anti-vasoconstrictive 
properties can be related to data that report estradiol inhibition of  ET-1 synthesis [197], possibly 
through E2 receptor-dependent pathways [202].  In an in-vitro study, Dubey et al., [203] 
treatment of porcine coronary artery endothelial cells with varying concentrations of estradiol 
and estradiol metabolites, 2-hydroxyestradiol and 2 methoxyestradiol, dependently inhibited 
basal and serum tumor necrosis factor-alpha, angiotensin II, and thrombin induced endothelin-1 
synthesis.  As compared with estradiol, its metabolites were shown to be more potent in 
inhibiting ET-1 secretion [203].  Confirmation of such findings in vivo is yet to be reported. 
7.3 AM Athletes and Endothelin:  No studies to date have reported on the endothelin-1 levels of 
young (18-35yrs) AM athletes or in AN patients.  However, in women of reproductive age, ET-
1evels are elevated during the menses phase when compared to the follicular and luteal phases 
[204].  Consistent with data in postmenopausal women, endogenous E2 also appears to favorably 
reduce circulating ET-1.  These findings lend credence to the hypothesis that ET-1 levels might 
be expected to be elevated in AM athletes.  However, it is known that chronic exercise causes an 
increase in production of nitric oxide and a decrease in production of ET-1 in humans [154], 
which may produce beneficial effects on the cardiovascular system.  Further, a significant 
negative correlation between plasma nitrite/nitrate concentration and plasma ET-1 concentrations 
has been demonstrated [154].  In support of this, data also show that exercise training diminishes 
the aortic sensitivity of ET-1 upon the vasculature [205], thereby necessitating less ET-1 to effect 
vasoconstriction or vasoregulation.    
The effect of chronic exercise upon ET-1 concentrations in AM athletes is unknown.  
Since previous data demonstrate diminished levels of nitrites/nitrates despite chronic training and 
elevated dietary nitrate intake in AM athletes [21], it can only be speculated that, similar to 
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postmenopausal women, ET-1 levels may be elevated, possibly due to decreased sensitivity to 
ET-1 and/or decreased circulating nitric oxide levels.  
 
8.0 Homocysteine 
8.1 Introductory Comments:  Homocysteine is an intermediate sulphur-containing amino acid 
produced in the metabolism of the essential amino acid methionine [206,207].  There are two 
major metabolic outcomes of homocysteine, the first being reversible trans-methylation [206].  
This leads to the reformation of methionine, as during methionine deficiency, and ensures a 
sufficient supply of methionine for protein synthesis [206].  Secondly, irreversible trans-
sulfuration which results in the eventual excretion of homocysteine as sulphate in the urine 
[206.207].   
 Homocysteine has been identified as an independent, modifiable risk factor for 
cardiovascular disease [208,209].  It is a recognized marker of systemic inflammation [13,210], 
and is an important mediator of atherosclerosis [207].  Mechanisms by which elevated 
homocysteine causes vascular disease include the direct toxic effects on the endothelium due to 
the generation of hydrogen peroxide formed in the process of homocysteine metabolism 
[206,207; 211].  This effect of increased free radical generation and subsequent lowered 
glutathione formation is suggested to be the principal cause for accelerated atherosclerosis [207].  
Other factors important to the atherosclerotic process that are also affected by elevated 
homocysteine levels include  proliferation of vascular smooth muscle cells [212], promotion of 
thrombosis [213], elevated collagen production in smooth muscle cells [214], stimulation of 
oxidization of LDL and anticoagulant inhibition [215].  Normal concentrations of fasting plasma 
homocysteine are somewhat varied, and range from 5-15 µmol/L [216], or ≤ 12µmol/L [217]. 
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Hyperhomocysteinemia may derive from either nutritional (i.e. inadequate dietary intake of 
folate, vitamin B12 or B6) or genetic (i.e. homocystinuria) origins [206,207].  Additional factors 
contributing to elevated homocysteine are age, gender, impaired kidney and liver function, and 
certain medications [17,206].   
8.2 Homocysteine in Postmenopausal Women:  The homocysteine-lowering effect of E2 is well 
documented [17,18,211,218]. E2 status is a non-genetic factor that affects homocysteine 
metabolism [218].  Decreased levels of homocysteine have been reported in pregnant [219], 
premenopausal [208,218,220] and postmenopausal women who are on ERT [17,18,221] 
compared to age-matched men, surgically menopausal women, and postmenopausal women who 
are not on ERT.  
8.3 Homocysteine in AM Athletes:   There are no data available to date regarding homocycsteine 
levels in AM athletes.  However, concerns regarding the homocysteine level of the AM athlete 
can be related to studies that show nutritional macro- and micro-nutrient intake of most female 
athletes to be less than might be anticipated based on their training load [222,223,224].  Intake of 
iron, calcium, vitamin B12 and zinc have also been reported to be below the recommended daily 
allowances among female athletes [223].   Since low folate concentrations have been identified 
as one of the key mediators of higher homocysteine levels [207], and reductions as great as 40% 
in plasma homocysteine concentrations with folate supplementation have been reported [225], 
the recommendation of sufficient dietary intake of folic acid may be particularly important for 
the AM athlete.  Interestingly, adolescent AN patients exhibit significantly increased 
homocysteine levels [226].  Further, young premenopausal women also exhibit menstrual phase 
dependent homocysteine concentrations, with the lowest concentrations coincident with elevated 
E2 levels [227].  Due to the identification of an E2- and folate-lowering effect on homocysteine, 
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it is possible that the AM may demonstrate subtle, but potentially significantly sustained elevated 
levels of homocysteine.  Since atherosclerosis is accelerated with even mild increments in 
homocysteine [228], this concern will be interesting to address. 
 
9.0  C-Reactive Protein 
9.1 Introductory Comments:  Atherosclerosis has recently been identified as an inflammatory 
disease marker [229].  Characteristic of most forms of inflammation or tissue damage is the 
elevated serum concentration of acute-phase reactants, such as C-reactive protein (CRP) 
[230,231]. As a recognized surrogate marker of low-grade systemic inflammation, CRP reflects 
heightened levels of pro-inflammatory cytokines [232]. Prospective studies have shown that CRP 
is a strong independent risk factor for CVD [13,232], as well as a predictive tool of relative risk 
for future events such as stroke [233].  Specifically, data indicate that CRP predicts vascular 
events among low-risk groups of women with no readily apparent markers for disease [234], and 
even in women with LDL levels below 3.37 mmol/L [13]. 
 Plasma CRP usually exists at very low concentrations, with 90% of individuals having a 
CRP <3.0 mg/L [235], but can be elevated several hundred-fold in response to infection [236].  It 
is important to note that as a non-specific acute phase response protein [237], CRP can be 
influenced by a number of factors, such as bacterial infection and inflammatory diseases [238], 
prolonged exercise, smoking, and age [237,238,239].  It is also positively associated with body 
mass index [236].  Despite the many influencing factors, CRP is still more precise than other 
markers of the acute-phase response, and is therefore considered an extremely useful marker of 
ongoing inflammation and/or tissue damage [237].  
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9.2  Postmenopausal Women and CRP:  The reported effects of E2 and HRT on CRP levels have 
recently been reviewed [240].  Most [234,241,242] but not all [243] studies demonstrate an E2-
mediated effect of CRP.  Indeed, a recent clinical trial showed an 85% average increase in CRP 
over 3 years with HRT when compared to placebo [241].  This E2-increasing effect has been 
confirmed in cross sectional [242] and prospective [234] studies, and at first glance, suggests that 
HRT may be pro-inflammatory [242].   However, the increase in CRP due to exogenous HRT is 
postulated to be metabolic rather than inflammatory [230]. Observation of decreased 
inflammatory markers, such as IL-6 and E-selectin, in the presence of elevated CRP, supports a 
possible link with the hepatic first-pass effect of oral hormone therapies on CRP plasma 
concentrations [230].  This postulate makes sense when considering that plasma CRP is 
produced solely by hepatocytes [237].  That chronic transdermal HRT treatment does not elevate 
plasma CRP levels [243] further supports a metabolic rather than pro-inflammatory effect of oral 
HRT.  The clinical relevance of these findings, however, are not known. 
9.3 AM Athletes and CRP:  Studies observing the effects of exercise on CRP in AM athletes have 
not been reported.  Further, data observing CRP levels in female athletes are sparse.  Fallon et 
al., [238] observed that an acute phase response, as determined by CRP, did not occur as a result 
of the levels of training typical of elite female athletes participating in court and field sports. 
These findings are consistent with data that demonstrate that strenuous endurance training is 
associated with an exercise-lowering effect on CRP concentrations [245,246]. The concept that 
training itself may attenuate the acute phase response, possibly by maintaining a ‘balance’ 
between response and anti-inflammation, has been demonstrated via long-term training studies 
that reveal a diminished acute phase reaction due to regular endurance exercise in men [245].  
The decrease of the CRP base-line level after chronic training suggest that intensive endurance 
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exercise training may have a systemic anti-inflammatory effect, which has been postulated to be 
linked with an enhanced exercise-associated antioxidative defense mechanism [245].  In contrast 
to these findings, exercise has also been allied with an inflammatory reaction in the blood [247].  
Cytoskeletal damage due to strenuous exercise can result in substantial tissue injury and clinical 
signs of transient immunosuppression [248].  That is, the anti-inflammatory response itself is 
also immunosuppressive, and can result in increased susceptibility to viral infections [248], a 
major stimulus of the CRP acute phase response [237].  
Both endurance running and downhill running generate muscle damage [247], and 
unaccustomed eccentric-biased exercise, whether due to unfamiliarity of the exercise, or the 
intensity or duration of the exercise, incurs muscle and tissue trauma that subsequently activates 
an acute inflammatory response [249].  Additionally, increased free-radical production due to 
tissue injury can further heighten the inflammatory response [248].  Running, ballet, and 
gymnastics are sports typically associated with amenorrhea [250], and are associated with 
eccentric-biased activities that provide a high potential for muscle and tissue damage.  If an 
enhanced oxidative defense mechanism does indeed confer generalized anti-inflammatory 
benefits [245], then it might be projected that AM athletes may demonstrate a compromised anti-
inflammatory capacity due to reduced circulating E2, a powerful anti-oxidant in itself [251].  
Together these factors may subsequently counter the chronic exercise-lowering effect on the 
acute phase response.  Elevated levels of CRP post training for the AM athlete could, therefore, 
be apparent.  On the contrary, chronically low E2 levels together with accustomed endurance 
activities may attenuate or even lower CRP levels.  However, since the effect of 
hypoestrogenism in younger athletes upon CRP levels has not yet been explored, these 
hypothetical outcomes remain to be discerned.   
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In addition to measurement of CRP as a method of determining increased risk of 
cardiovascular disease, IL-6 has also been hypothesized as a good marker of cardiovascular 
health in apparently healthy individuals [252]. Indeed, synthesis of CRP in the liver is 
predominantly modulated by [253] and strongly correlated with [254] the cytokine interleukin-6 
(IL-6), although IL-6 and CRP are independently related to several clinical cardiovascular risk 
factors in women [255].  IL-6 not only regulates immune system responses [256], but also 
increases fibrinogen, blood viscosity, platelet numbers, and activity [240].  Overtraining [256] 
and nutrient status [257] have been shown to impact pro-inflammatory cytokine levels.  
Consequences of a low calorie diet together with strenuous exercise stress may induce elevated 
IL-6 and cortisol levels in female athletes [258].  The nutrient status of the AM athlete frequently 
reveals suboptimal energy and nutrient intake which is linked with compromised immune 
responses [258], although data show no relation between susceptibility to infections and 
menstrual status in recreationally active women [259].  Since cytokine levels, particularly IL-6, 
increase with strenuous endurance activities [260], this finding suggests that exercise intensity 
and duration rather than menstrual status impacts the immune response.  Interestingly, in 
malnourished individuals such as AN patients, there is an atypical, unexpected finding of lack of 
viral infections, or minimal symptoms in response to minor viral infections despite poor nutrient 
status [257]. The mechanisms behind this response have not been ascertained, but it is suggested 
to be a protective adaptation which is lost during refeeding [257].  Decreased IL-6 levels in AN 
patients [257] suggest that a lowered CRP status may be present.  Whether hypoestrogenism per 
se in these patients imparts an effect on IL-6 or CRP is not clear.  
In addition to decreased IL-6, persistently elevated levels of cortisol, which ordinarily 
reduces cytokine responses in healthy individuals, does not convey reduced inflammatory 
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responses in AN patients [257].  This response identifies that the feedback mechanism is 
somehow rendered ineffective, impairing the ability to establish an acute-phase response [257].  
AM athletes also demonstrate elevated cortisol levels compared to their EU peers [261], but it is 
not known whether this has any impact on acute phase protein concentrations.  Due to the 
similarity between AM athletes and AN patients, the presence of similar immune cell responses 
may be revealed.    
 
10.0  Conclusion  
10.1  Comments and Conclusions:  The synthesis of findings secondary to the effects of 
hypoestrogenism in young female AM athletes upon cardiovascular outcomes discussed in this 
paper lend credence to the postulate that these women may be at an increased risk of premature 
CVD, extending the clinical sequelae of the Female Athlete Triad to cardiovascular concerns. 
Despite several inconsistencies with regard to statistical significance and cardiovascular 
outcomes, largely due to small sample sizes, it can not be dismissed that sustained unfavorable 
alterations to markers of cardiovascular health may prove to have long-term deleterious 
subclinical clinical effects.  Unfavorable changes in  LDL, lipid peroxidation potential, TC, TG, 
and endothelial function, despite a physically active lifestyle, suggest that AM athletes may 
potentially be  susceptible to increased cardiovascular risk. This risk should be acknowledged as 
part of the already recognized sequelae of the Female Athlete Triad associated with amenorrhea 
in athletes.  More studies, specifically longitudinal and prospective studies need to be performed 
to help discern the long-term effects of hypoestrogenism on cardiac and vascular function in 
young athletic women and to determine if the aforementioned unfavorable changes observed 
represent a clinically significant increase in CVD risk.  
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